Proposals should:

  • increase patient access to advanced therapy medicinal products (ATMPs) on a national level
  • establish best practice for the safe and effective delivery of ATMPs to patients
  • establish best practice for the manufacturing and final preparation of ATMPs using Good Manufacturing Practice (GMP) within a clinical setting
  • establish robust connected supply chains for the manufacture and delivery of ATMPs
  • create systems to allow traceability and tracking of ATMPs. These must be compatible with current regulations and be suitable for applying across the NHS
  • establish best practice for patient follow up and data capture

All of the centres that receive funding will form a network. This will be co-ordinated through the Cell and Gene Therapy Catapult.

The 3 successful centres will eligible to apply for up to £6 million of additional funding in 2018 for network projects and related activities.

Total project costs should be between £6 million and £9 million.